Kopran Ltd

Kopran Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kopran Ltd

₹ 257 -3.46%
19 Apr - close price
kopran.com BSE: 524280 NSE : KOPRAN
About

Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.

The export percentage is about 65% of the total sales.

Key Points

API Vertical (57%) [1]
Development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. One of the leaders in Atenolol & one of the major players in Sterile Carbapenems. Their main products are Sterile Carbapenems (36%), Anti-Hypertensive (17%), and Macrolides (~16%). API vertical is operated by WOS Kopran Research Laboratories. [2] [3]

Website BSE NSE
  • Market Cap ₹ 1,238 Cr.
  • Current Price ₹ 257
  • High / Low ₹ 292 / 140
  • Stock P/E 30.7
  • Book Value ₹ 91.6
  • Dividend Yield 1.17 %
  • ROCE 8.30 %
  • ROE 6.29 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 32.6%

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
112 140 75 128 132 143 126 117 158 149 117 153 159
91 121 66 104 105 117 112 107 146 137 111 130 135
Operating Profit 21 19 9 24 27 26 13 10 12 12 6 23 24
OPM % 19% 14% 12% 19% 21% 18% 10% 9% 8% 8% 5% 15% 15%
4 5 3 3 4 2 1 0 2 4 2 0 2
Interest 2 1 1 1 2 1 1 1 2 2 2 2 2
Depreciation 2 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax 21 20 8 23 27 24 10 6 9 11 4 18 20
Tax % 26% 26% 24% 25% 25% 27% 24% 23% 24% 26% 23% 25% 23%
16 15 6 17 20 18 8 5 7 8 3 14 16
EPS in Rs 3.63 3.48 1.47 3.95 4.64 3.63 1.58 0.96 1.44 1.67 0.57 2.86 3.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
199 250 303 326 296 310 313 358 360 492 478 551 577
178 217 260 294 266 274 283 312 313 410 390 499 513
Operating Profit 21 34 43 31 30 36 31 46 47 82 87 52 65
OPM % 11% 13% 14% 10% 10% 12% 10% 13% 13% 17% 18% 9% 11%
6 2 2 -48 1 11 9 3 -0 18 11 3 9
Interest 10 12 14 13 13 14 9 9 9 6 5 6 8
Depreciation 12 12 13 10 8 8 9 9 10 10 11 13 13
Profit before tax 5 11 17 -39 11 25 23 32 28 83 82 36 53
Tax % 0% 0% 0% 0% 0% 20% 10% 24% 26% 26% 25% 24%
5 11 17 -39 11 20 20 24 21 62 61 27 40
EPS in Rs 1.37 2.85 4.40 -9.52 2.48 4.60 4.74 5.55 4.86 14.24 12.66 5.65 8.38
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 21% 24% 53%
Compounded Sales Growth
10 Years: 8%
5 Years: 12%
3 Years: 15%
TTM: 6%
Compounded Profit Growth
10 Years: 9%
5 Years: 6%
3 Years: 8%
TTM: 10%
Stock Price CAGR
10 Years: 24%
5 Years: 45%
3 Years: 24%
1 Year: 72%
Return on Equity
10 Years: 15%
5 Years: 15%
3 Years: 15%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 39 39 39 41 43 43 43 43 43 43 48 48 48
Reserves 38 50 67 35 57 81 101 125 146 202 378 391 393
Preference Capital 9 9 9 9 9 0 9 6 0 0 0 0
103 103 129 77 71 95 80 91 88 66 75 75 93
70 72 64 122 93 78 90 91 92 128 110 135 144
Total Liabilities 250 263 299 275 264 298 315 351 370 439 611 650 678
114 109 105 102 101 104 104 113 111 112 151 165 193
CWIP 19 20 20 1 3 6 10 24 30 43 36 70 63
Investments 1 1 1 0 0 0 0 0 0 0 0 0 0
116 134 174 172 160 187 201 214 229 284 425 415 422
Total Assets 250 263 299 275 264 298 315 351 370 439 611 650 678

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
35 15 3 46 29 16 26 25 31 60 -33 34
-10 -9 -9 -10 -9 -18 -11 -25 -13 -25 -84 -13
-19 -12 7 -37 -19 2 -15 -1 -18 -35 123 -20
Net Cash Flow 6 -7 0 -0 0 -0 -0 -0 0 0 5 2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 72 75 68 91 70 86 75 88 94 89 97 108
Inventory Days 101 87 103 78 119 122 138 129 154 121 202 133
Days Payable 120 111 69 119 115 95 118 90 95 104 84 89
Cash Conversion Cycle 52 50 101 50 74 113 96 127 153 106 215 152
Working Capital Days 59 74 108 67 80 109 121 117 126 113 200 177
ROCE % 8% 12% 14% 14% 14% 19% 14% 16% 14% 30% 21% 8%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
43.78% 43.78% 43.78% 44.25% 44.25% 44.25% 44.29% 44.29% 44.49% 44.49% 44.49% 44.49%
0.16% 0.27% 0.75% 0.53% 0.50% 0.51% 0.34% 0.41% 0.34% 0.39% 0.48% 0.84%
0.69% 0.46% 0.16% 0.14% 0.13% 0.14% 0.14% 0.14% 0.14% 0.35% 0.14% 1.20%
55.37% 55.50% 55.31% 55.07% 55.11% 55.09% 55.22% 55.15% 55.03% 54.78% 54.88% 53.47%
No. of Shareholders 40,51238,19537,82239,90640,88341,76842,03441,56744,03853,79151,63650,850

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls